IOVANCE BIOTHERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $6.40M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $99.31M | $-0.11 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | Before market open | $86.71M | $-0.18 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $67.46M | $-0.25 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | $73.70M | $-0.26 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | $31.10M | $-0.34 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| total revenue guidance | FY26 | $350.00M to $370.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Iovance Biotherapeutics filed with the SEC
1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview October 2026 1
Other events · EX-99.1 to Form 8-K
Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Other events · EX-99.1 to Form 8-K
© 2026, Iovance Biotherapeutics, Inc.
Other events · EX-99.1 to Form 8-K
Biotherapeutics Reports Record Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview June 2026 1
Other events · EX-99.1 to Form 8-K
the Treatment of Advanced Melanoma in Australia
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Results, Business Achievements and Corporate
Results of operations · EX-99.1 to Form 8-K
Iovance Biotherapeutics Highlights Strong Fourth
Results of operations · Other events · EX-99.1 to Form 8-K
1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview February 2026 1
Results of operations · Other events · EX-99.2 to Form 8-K
1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview January 2026 1
Other events · EX-99.1 to Form 8-K
Pipeline Milestones, and Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
© 2025, Iovance Biotherapeutics, Inc.
Other events · EX-99.1 to Form 8-K
First T cell therapy for a solid tumor cancer
Other events · EX-99.1 to Form 8-K
Iovance Biotherapeutics Reports Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Iovance Biotherapeutics Appoints Corleen Roche
Executive or director change · Other events · EX-99.1 to Form 8-K
Iovance Biotherapeutics Reports Financial Results
Results of operations · EX-99.1 to Form 8-K
Iovance Biotherapeutics Reports Financial Results
Results of operations · EX-99.1 to Form 8-K
Iovance Biotherapeutics Appoints Dan Kirby as
Other events · EX-99.1 to Form 8-K
1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview November 2024 1
Other events · EX-99.1 to Form 8-K
Iovance Biotherapeutics Reports Financial Results
Results of operations · EX-99.1 to Form 8-K
1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview August 2024 1
Other events · EX-99.1 to Form 8-K
Iovance Biotherapeutics Reports Financial Results
Results of operations · EX-99.1 to Form 8-K
Iovance Biotherapeutics Submits Marketing Authorization
Other events · EX-99.1 to Form 8-K
1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview May 31, 2024 1
Other events · EX-99.1 to Form 8-K
Frontline Advanced Melanoma at ASCO 2024 Annual
Other events · EX-99.1 to Form 8-K
Iovance Biotherapeutics Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
IAIN DUKES, D.PHIL., MARIA FARDIS,
Other events · EX-99.1 to Form 8-K
Iovance Biotherapeutics Announces FDA has Lifted
Other events · EX-99.1 to Form 8-K
1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview February 28, 2024 1
Other events · EX-99.1 to Form 8-K
Iovance Biotherapeutics Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Iovance Biotherapeutics, Inc. Announces Pricing of $211
Material agreement · Other events · EX-99.1 to Form 8-K
Receives U.S. FDA Accelerated Approval
Results of operations · Other events · EX-99.1 to Form 8-K
1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview February 16, 2024 1
Results of operations · Other events · EX-99.2 to Form 8-K
1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview January 25, 2024 1
Other events · EX-99.1 to Form 8-K
1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview January 2024 1
Other events · EX-99.1 to Form 8-K
Iovance Biotherapeutics Announces Clinical Program Update for LN-145
Other events · EX-99.1 to Form 8-K
Iovance Biotherapeutics Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
U.S. Food and Drug Administration Updates
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
1 © 2023, Iovance Biotherapeutics, Inc. © 2023, Iovance Biotherapeutics, Inc. Corporate Overview August 16, 2023 1
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K